Načítá se...
Tremelimumab-Induced Graves Hyperthyroidism
Tremelimumab and ipilimumab are monoclonal antibodies directed against the extracellular domain of cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and have been used as immunotherapies against immune checkpoints that suppress T-cell activation. Anti-CTLA-4 antibody-based therapies have been sho...
Uloženo v:
| Vydáno v: | Eur Thyroid J |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
S. Karger AG
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5527187/ https://ncbi.nlm.nih.gov/pubmed/28785544 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000464285 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|